Attaching a kind of molecule backpack to myeloid cells — a type of immune cells involved in the inflammatory attack that drives multiple sclerosis (MS) — may help to halt inflammation and damage in the brain in MS by modulating immune cell activity, a study…
MS relapse
The recently approved CD20 inhibitor Briumvi (ublituximab-xiiy) has received a permanent insurance reimbursement code that will simplify claims submissions and documentation processes for adults in the U.S. with relapsing forms of multiple sclerosis who are prescribed it. Issued by the U.S. Centers for Medicare and Medicaid Services, the…
More than 80% of patients with relapsing forms of multiple sclerosis (MS) given Kesimpta (ofatumumab) continuously for up to five years in a clinical trial did not have any documented worsening of disability over the duration of the treatment. That’s according to new data from the ongoing…
There was no evidence of multiple sclerosis (MS) disease activity for at least two years in patients who underwent an autologous hematopoietic stem cell transplant (aHSCT) at a center in Mexico. And by the most recent follow-up — a median of about seven years after the procedure —…
Treatment with Aubagio (teriflunomide) significantly reduces the risk that adults with radiologically isolated syndrome (RIS) will develop symptoms of multiple sclerosis (MS), new clinical trial data show. This is the second trial showing that approved disease-modifying therapies can delay the development of MS in people who have…
About 2.5 years of treatment with tolebrutinib was associated with low relapse rates and stable disability levels among people with relapsing forms of multiple sclerosis (MS), according to data in an ongoing, open-label extension of a Phase 2b trial. The oral treatment also continued to show a “favorable”…
A high-dose vitamin D supplement did not reduce the risk of relapses in people with relapsing-remitting multiple sclerosis (RRMS) already using a disease-modifying therapy to control disease activity, according to findings of a Phase 3 clinical trial. The VIDAMS study (NCT01490502) — standing for Vitamin D…
The U.S. Food and Drug Administration (FDA) has placed a partial clinical hold on ongoing trials of evobrutinib, Merck KGaA’s experimental BTK inhibitor for relapsing forms of multiple sclerosis (MS). The decision was based on two cases of patients in Phase 3 clinical trials of evobrutinib who were…
The benefits of Mavenclad (cladribine) were sustained for up to 15 years after its last treatment course in people with relapsing multiple sclerosis (MS), according to real-world data from the CLASSIC-MS study. More than half of those who received the oral therapy in the clinical trials that supported…
One year of treatment with Lemtrada (alemtuzumab) significantly improved cognitive abilities, particularly with processing speed, and eased depression in people with relapsing forms of multiple sclerosis (MS), a small real-world study reported. Most of the 39 patients (92%) evaluated after that treatment year showed either stable or improved…
Early treatment with Mavenclad (cladribine) or monoclonal antibodies is more likely to control symptoms in people with highly active multiple sclerosis (MS), a study in Argentina suggests. Highly active disease usually is considered when frequent relapses occur and there is an increasing burden of brain magnetic resonance imaging…
An arm of the European Medicines Agency favors the approval of Briumvi (ublituximab) to treat adults with active, relapsing forms of multiple sclerosis (MS) across the European Union (EU). The Committee for Medicinal Products for Human Use (CHMP) opinion is based on data from twin Phase 3 trials,…
Photo courtesy of Kellie Alderton Day 30 of 31 This is Kellie Alderton‘s story: I was 17 years old in 1988 when my body just stopped working. I had played softball for over a decade, but at my first practice that season I missed an easy fly…
Photo courtesy of Samantha Zarek Day 29 of 31 This is Samantha Zarek’s story: July 26, 2006 is a date I will always remember: That was the onset of my symptoms. My mom had emergency surgery that morning and when I told her that I saw two of…
Photo courtesy of Lucinda Howard Day 28 of 31 This is Lucinda Howard’s story: I was in the first few months of my first “adult” job when I suddenly felt numbness and tingling on my skin from my ribs down to my feet and in my hands. I went…
Photo courtesy of Lindsey Holcomb Day 24 of 31 This is Lindsey Holcomb’s story: My daughters were both preschoolers when I was diagnosed with relapsing-remitting multiple sclerosis (RRMS). It took well over a decade to find an answer to the myriad symptoms that had come and…
Jessica Dubey, right, is with her partner, Tom. (Courtesy of Jessica Dubey) Day 22 of 31 This is Jessica Dubey‘s story: Multiple sclerosis is unpredictable, You never quite know what to expect or how you will feel. Planning a weekend, a holiday, or even just…
Disease relapses are no more likely in women with multiple sclerosis (MS) after fertility treatment than they were before such treatment, a study found. Researchers also observed that almost half of the women receiving fertility treatment were on disease-modifying MS therapies, which may have helped to keep a…
Most neurologists in the U.S. are aware of the recent approval of Briumvi (ublituximab-xiiy) for the treatment of relapsing forms of multiple sclerosis (MS) and about half anticipate testing the therapy in the next six months, according to an analysis by market research company Spherix Global Insights. The therapy, developed…
Photo courtesy of Ashley Ratcliff Day 19 of 31 This is Ashley Ratcliff’s story: Fatigued, sore, and tingling, yet determined. Every Friday I fight the urge to surrender to my ever-long list of to-dos and the voice in my head telling me to sit this one out. Instead,…
If you noticed my sudden disappearance, it wasn’t because I was sacked. Surprising, I know. Just “MS MIA” — missing in action with multiple sclerosis. While raving in the hospital, I was suddenly moved to my own private room. In Britain’s National Health Service (NHS), this could only mean…
Photo courtesy of Scarlett Ward Day 16 of 31 This is Scarlett Ward‘s story: My name is Scarlett Ward, and I’m 29 years old. I was diagnosed with multiple sclerosis (MS) when I was 27, after a particularly nasty relapse left me in the hospital,…
Higher blood levels of Ocrevus (ocrelizumab) is associated with a significantly lower risk of confirmed disability progression during treatment in people with relapsing and progressive forms of multiple sclerosis (MS), according to an analysis of data from three Phase 3 clinical trials. Notably, the lower disability progression rates reported in…
Photo courtesy of Amber Cunningham Day 12 of 31 This is Amber Cunningham‘s story: Hi, I am Amber. I was diagnosed with multiple sclerosis (MS) in April 2019, a day I will never forget. I woke up on my daughter’s birthday and couldn’t see out…
Photo courtesy of Julie Wigley Day 11 of 31 This is Julie Wigley‘s story: In 2010, I started having numbness in my legs, specifically when I’d look down. I didn’t think much of it, but mentioned it to my primary care doctor during a…
Neurologists in the U.S. are generally favoring more aggressive early treatment for multiple sclerosis (MS), according to an analysis by market research company Spherix Global Insights. With over a dozen therapies available in the U.S. to treat relapsing forms of MS, patients and providers have options to…
GA Depot, an experimental long-acting version of glatiramer acetate, significantly reduced relapse rates and prevented the development of new lesions among people with relapsing forms of multiple sclerosis, according to new data from a Phase 3 clinical trial. Disability levels also were significantly reduced with the treatment, given…
Photo courtesy of Susan Payrovi Day 6 of 31 This is Susan Payrovi’s story: As a young person, physician, and new mom, I never expected to get sick. In fact, I considered myself to be the picture of health. What I failed to see were all of the factors…
Jessica (left) with her daughter, Jaleece. Photo courtesy of Jessica Lovato. Day 3 of 31 This is Jessica Lovato’s story: My name is Jessica, and I’m from Utah. In mid-February 2020, I was nine months into owning and operating a full-service salon and barbershop. As I was finishing a…
Every once in a while, I wake up prepared to swing my legs over the side of the bed and get moving. That sleep-induced forgetfulness evaporates as soon as the reality of multiple sclerosis (MS) reminds me that I can’t swing anything. I suppose I should be grateful that…